Antibiotic resistance of bacteria responsible of acute respiratory tract infections in children

Makhtar Camara,1 Assane Dieng,1 Abdoulaye Diop,1 Amadou Diop,1 Amadou Diop,2 Djibril Boiro,3 Jean Baptise Niokhor Diouf,4 Amary Fall,2 Ousmane Ndiaye,3 Mbayame Niang,5 Cheikh Saad Bouh Boye1

1Bacteriology and Virology Laboratory, Le Dantec teaching Hospital, Dakar; 2Bacteriology and Virology Laboratory, Albert Royer teaching Hospital, Dakar; 3Paediatric Unit, Abass NDAO Teaching Hospital, Dakar; 4Paediatric Unit, Roi Baudouin Hospital, Dakar; 5Medical Virology Unit, Institute Pasteur, Dakar, Senegal

Summary

Background and aims. Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the most common causative agents of acute respiratory tract infections (RTIs). The objective of this study was to assess their susceptibility to several antibiotics.

Materials and methods. A total of 58 strains (16 S. pneumoniae, 19 H. influenzae and 23 M. catarrhalis) were isolated from samples collected in two paediatric centres, and their susceptibility to commonly used antibiotics tested by E-test.

Results. Among H. influenzae isolates, 10.5% were resistant to ampicillin (all β-lactamase-positive), and 88.9% were susceptible to cefaclor. High β-lactam resistance rates (penicillin: 31.3% and cephalosporins: 18.7 to 31.3%) had been observed among S. pneumonia strains. Only 50% of isolates were susceptible to azithromycine. 91.3% of M. catarrhalis isolates β-lactamases producers were resistant to ampicillin while susceptible to the most tested antibiotics.

Conclusions. Except M. catarrhalis β-lactamases producing strains, frequency of antibiotic resistance was mainly observed among S. pneumoniae, and to a lesser extent among H. influenzae clinical isolates, suggesting the need for continuous surveillance of antimicrobial resistance patterns in the management of RTIs.

Introduction

Respiratory tract infections (RTIs) are the main cause of morbidity and mortality worldwide (7). Such diseases mainly involve bacteria such as Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. In Africa, acute respiratory infections induce 16% of death in children under 5 years old (15). Despite this high burden, there are few studies reporting updates of antimicrobial susceptibility of respiratory pathogens in Africa (8). There are limited antimicrobial surveillance data in Africa, and results from one country may not be applicable to another because of epidemiological discrepancies.

This makes surveillance of antibiotic resistance very important for guiding empirical therapy, especially in Africa, where health structures and patients must often rely on affordable first-line antibiotics that may have lost their clinical effectiveness (8).

Effective empirical therapy of bacterial diseases requires knowledge on local antimicrobial resistance (AMR) patterns since respiratory tract infection are usually treated without identification of the causal agent or its antibiotics susceptibility profile.

The objectives of this study were to identify these clin-
tical isolates, and to assess their susceptibility to several antibiotics.

Materials and methods

Sample collection

We analysed data from paediatric samples collected in patient aged between 1 to 60 months visiting two medical centers (Abass NDAO teaching hospital and Roi BAU-DOUIN hospital in Dakar, Senegal).

From October 2014 to October 2015, sputum (21), bronchoalveolar lavage (19), acute otitis media effusions (01), blood (01), sinus fluids (11), and throat swab (05) samples were collected and referred to the biotechnology unit of the laboratory of bacteriology and virology of Aristide Le Dantec university teaching hospital for routine bacterial tests.

The samples were immediately cultured and the strains isolated were then identified according to the standard methods of microbiology. *H. influenzae*, *S. pneumoniae*, and *M. catarrhalis* strains were identified if the bacterial load was at least 10^5 CFU/mL.

Identification of bacterial isolates

*H. influenzae* was identified by its macroscopic aspects in culture (such as the growth of tiny, moist, and smooth grey colonies) as well as metabolic characteristics: absence of haemolysis, positive catalase and oxidase tests, growth in simultaneous presence of X and V factors, satellite growth around streaks of *Staphylococcus aureus*, and other biochemical features using API NH® galleria (BioMerieux, Marcy-l’Etoile, France).

*M. catarrhalis* was identified by the presence of tiny, round, and smooth colonies; absence of haemolysis; positive catalase and oxidase tests; and others biochemical characters using API® NH galleria (BioMerieux, France).

*S. pneumoniae* was identified by the presence of tiny, round, flat, and transparent colonies with central depression (checker piece and nail head colonies); haemolysis of α-viridans; negative catalase and oxidase tests; absence of bile-esculin hydrolysis; lysis by bile-salts; susceptibility to optochin; and other biochemical characters using API® Strep (BioMerieux, France).

Antibiotic susceptibility testing

E-test method was used to study the antibiotic susceptibility of the three pathogens. Bacterial suspensions of each of the three pathogens were diluted to obtain a final concentration of 10^5 CFU/mL (an optical density of 0.5 on the McFarland scale) and inoculated on Haemophilus Test Medium for *H. influenzae*, on chocolate agar supplemented with Polyvitex® for *M. catarrhalis*, and on Mueller-Hinton supplemented with 5% sheep blood for *S. pneumoniae*.

Strips (E-test, bioMerieux SA, LYON) containing selected antibiotics were then placed on the inoculated plates. Plates were then incubated at 37°C under CO₂ atmosphere for 18-24 hours. Quality control for antimicrobial susceptibility testing was performed using the ATCC 49247 strain of *H. influenzae*, ATCC 49619 strains of *S. pneumoniae*. All antibiotics displayed acceptable minimal inhibitory concentrations (MICs) values compared to the control strains.

MICs were calculated as MIC₉₀ (MIC inducing inhibition of 50% of isolates) and MIC₉₉ (MIC inducing inhibition of 90% of isolates). Percentages of susceptibilities were determined based on Clinical Laboratory Standards Institute (CLSI) break points (4).

Beta-lactamase tests

The production of beta-lactamase has been investigated for *H. influenzae* and *M. catarrhalis* isolates using a nitrocefin-based test (Cefinase, Becton Dickinson Microbiology Systems, and Cockeysville, MD, USA).

Analysis of results

WHONET software (version 6) was used to analyse results of the antibacterial susceptibility test. MIC₅₀ and MIC₉₀ were calculated.

Results

In this study, 58 isolates (19 of *H. influenzae*, 16 *S. pneumoniae* and 23 of *M. catarrhalis*) have been identified and tested for antibiotic susceptibility.

**Antibiotic susceptibility testing of *H. influenzae***

The results of susceptibility testing for *H. influenzae* isolates are summarized in Table 1.

All *H. influenzae* isolates were susceptible to amoxicillin/clavulanic acid (MIC₉₀=1 mg/L), cefalosporins (cefuroxim MIC₉₀=3 mg/L, cefixim MIC₉₀=0.094 mg/L), fluoroquinolones (ciprofloxacin: MIC₉₀=0.094 mg/L; levofloxacin: MIC₉₀=0.023 mg/L; ofloxacin: MIC₉₀=0.016 mg/L), and azithromycin (MIC₉₀=2 mg/L). However, resistance patterns to ampicillin (10.5%), cefaclor (11.2%) and /sulamethoxazole/trimethoprim (100%) were observed. All ampicillin-resistant isolates produced β-lactamase.

**Antibiotic susceptibility testing of *S. pneumoniae***

Table 2 shows an overview of antibiotic susceptibility rates of *S. pneumoniae*. High β-lactams resistance rates had been observed among *S. pneumoniae* strains, including penicillin G (31.3%), cefalosporins (18.7 to 31.3%). All isolates were resistant to sulfamethoxazole/trimethoprim (100%). Only 50% of *S. pneumoniae* isolates were susceptible to azithromycin while all isolates were susceptible to fluoroquinolone antibiotics (levofloxacin MIC₉₀=1 mg/L, ofloxacin MIC₉₀=2 mg/L) and clindamycin (MIC₉₀=0.19 mg/L).

**Antibiotic susceptibility testing of *M. catarrhalis***

All *M. catarrhalis* isolates were susceptible to amoxicillin/clavulanic acid (MIC₉₀=0.5 mg/L) and macrolides (azithromycin MIC₉₀=0.75 mg/L, clarithromycin MIC₉₀=1.5 mg/L) (Table 3). Fluoroquinolones tested...
showed very good activity (100% and 95.2% for levofloxacin and ciprofloxacin, respectively), with low MIC\textsubscript{90} (0.094 mg/L). Among isolates tested, 95.7% were susceptible to cefuroxim and cefaclor. However, 91.3% of *M. catarrhalis* isolates positive for β-lactamase were resistant to ampicillin (data not shown).

### Table 1. Susceptibility of *Haemophilus influenzae* isolates.

| Antibiotics                        | R, %  | S, %  | MIC\textsubscript{50}, mg/L | MIC\textsubscript{90}, mg/L | Range, mg/L |
|-----------------------------------|-------|-------|----------------------------|-----------------------------|-------------|
| Ampicillin                        | 10.5  | 89.5  | 0.25                        | 1                           | 0.04-1.5    |
| Amoxicillin/clavulanic acid       | 0     | 100   | 0.5                         | 1.5                         | 0.125-2     |
| Cefuroxim                         | 0     | 100   | 1                           | 3                           | 0.19-4      |
| Cefaclor                          | 11.2  | 88.9  | 3                           | 16                          | 1.5-48      |
| Cefixim                           | 0     | 100   | 0.047                       | 0.094                       | 0.016-0.38  |
| Ciprofloxacin                     | 0     | 100   | 0.016                       | 0.023                       | 0.003-0.023 |
| Levofloxacin                      | 0     | 100   | 0.012                       | 0.016                       | 0.006-0.016 |
| Ofloxacin                         | 0     | 100   | 0.032                       | 0.047                       | 0.016-0.047 |
| Sulfamethoxazole/trimethoprim     | 100   | 0     | 32                          | 32                          | 0.75-32     |
| Azithromycin                      | 0     | 100   | 1                           | 2                           | 0.38-2      |
| Clarithromycin                    | 5.3   | 94.7  | 4                           | 8                           | 1.5-12      |

R, Resistant; S, Susceptible; MIC, Minimum Inhibitory Concentration.

### Table 2. Susceptibility of *Streptococcus pneumonia* isolates.

| Antibiotics                        | R, %  | S, %  | MIC\textsubscript{50}, mg/L | MIC\textsubscript{90}, mg/L | Range, mg/L |
|-----------------------------------|-------|-------|----------------------------|-----------------------------|-------------|
| Penicillin G                      | 31.3  | 68.7  | 0.032                       | 0.125                       | 0.006-0.5   |
| Amoxicillin/clavulanic acid       | 12.5  | 87.5  | 0.032                       | 0.032                       | 0.001-1     |
| Cefuroxim                         | 18.7  | 81.3  | 0.047                       | 0.38                        | 0.016-1.5   |
| Cefaclor                          | 31.3  | 68.7  | 0.75                        | 1.5                         | 0.094-2     |
| Cefixim                           | 24.5  | 75.5  | 0.38                        | 1.5                         | 0.125-1.5   |
| Levofloxacin                      | 0     | 100   | 0.5                         | 1                           | 0.38-1      |
| Ofloxacin                         | 0     | 100   | 1.5                         | 2                           | 1-2         |
| Sulfamethoxazole/trimethoprim     | 100   | 0     | 3                           | 32                          | 0.064-32    |
| Clindamycin                       | 0     | 100   | 0.094                       | 0.19                        | 0.016-0.25  |
| Azithromycin                      | 50    | 50    | 0.5                         | 1.5                         | 0.016-1.5   |
| Clarithromycin                    | 19.7  | 81.3  | 0.064                       | 0.125                       | 0.016-0.125 |

R, Resistant; S, Susceptible; MIC, Minimum Inhibitory Concentration.

### Table 3. Susceptibility of *Moraxella catarrhalis* isolates.

| Antibiotics                        | R, %  | S, %  | MIC\textsubscript{50}, mg/L | MIC\textsubscript{90}, mg/L | Range, mg/L |
|-----------------------------------|-------|-------|----------------------------|-----------------------------|-------------|
| Amoxicillin/clavulanic acid       | 0     | 100   | 0.064                       | 0.5                         | 0.016-3     |
| Cefuroxim                         | 4.3   | 95.7  | 0.75                        | 2                           | 0.064-12    |
| Cefaclor                          | 4.3   | 95.7  | 1.5                         | 2                           | 0.38-12     |
| Cefixim                           | 0     | 100   | 0.125                       | 0.5                         | 0.047-0.5   |
| Ciprofloxacin                     | 4.8   | 95.2  | 0.032                       | 0.094                       | 0.012-0.25  |
| Levofloxacin                      | 0     | 100   | 0.032                       | 0.094                       | 0.012-0.25  |
| Sulfamethoxazole/trimethoprim     | 0     | 100   | 0.25                        | 0.25                        | 0.25-0.25   |
| Azithromycin                      | 0     | 100   | 0.064                       | 0.75                        | 0.023-0.75  |
| Clarithromycin                    | 0     | 100   | 0.047                       | 1.5                         | 0.023-1.5   |

R, Resistant; S, Susceptible; MIC, Minimum Inhibitory Concentration.

**Discussion**

The results from this study indicate a low frequency (10.5%) of *H. influenzae* beta-lactamase producing strains, all resistant to ampicillin. Our results are in agreement with...
findings from a previous study conducted in Dakar (10) and in other countries such as Italia (2), Northen Taiwan (14), Cuba (13), and South Africa (5). This suggests that beta-lactamase production could be the major mechanism of antibiotic resistance for these organisms.

A high rate (100%) of H. influenzae resistance to cotrimoxazole was observed, contrasting therefore with results reported by Gueye et al., in Dakar in 2009 (10).

The cephalosporins, fluoroquinolones, and macrolides antimicrobial families were active and could therefore be used as alternative options in RTI treatment.

Penicillin G resistance in S. pneumoniae infection was observed in Africa as well as in other countries (1,6). In our study, high resistance rate (31.3%) of S. pneumoniae to penicillin G was observed, which is similar to data previously reported in a study conducted by Gueye and al. in Dakar (10). However, our data are not consistent with results reported in Sub-Saharan Africa in which resistance level remained below 6% overall (12). This is similar to findings from West Africa, especially in Gambia where surveillance studies have been carried out extensively and showed that only 6.6% of the isolates had intermediate resistance and none had full resistance to penicillin (3). Resistance to sulfamethoxazole/trimethoprim were detected in all isolates tested. This is in disagreement with results from a study conducted in Dakar in 2009 (10). However, increasing resistance rates to sulfamethoxazole/trimethoprim have been reported between 2003 and 2006 in the East Africa region (9).

M. catarrhalis isolates showed high susceptibilities towards most of the antibiotics tested, except for beta-lactamase positive strains for which higher rate of resistance (91.3%) was observed. In our study, we observed that beta-lactamase production was the primary mechanism of ampicillin resistance for M. catarrhalis; all isolates that were resistant to ampicillin were beta-lactamase producer. Similar results were observed in a previous surveillance study conducted in other parts of the world (11).

Conclusions

In summary, the results from this study indicate that none of the isolates exhibited multiple resistances patterns. Except M. catarrhalis ampicillin-resistant beta-lactamases producing strains, frequency of antibiotic resistance was mainly observed among S. pneumoniae, and to a lesser extent among H. influenzae clinical isolates. Overall, cephalosporins, fluoroquinolones, and macrolides remain active on these three pathogens and could be used as alternative treatment for RTIs in association with continuous surveillance of antimicrobial resistance patterns.

References

1. Benbachir M, Benredjed S, Boye CS, et al. Two-year surveillance of antibiotic resistance in S. pneumoniae in four African cities. Antimicrob Agents Chemother 2001;45:627-9.
2. Cardines R, Guifre M, Pompei A, et al. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol 2012;302:45-52.
3. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of S. pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 2009;28:990-5.
4. Clinical and Laboratory Standards Institute. M100-S16. Performance standards for antimicrobial disc susceptibility tests; Sixteenth edition. Approved Standard. Wayne: PA: CLSI 2006.
5. Crowther-Gibbon F, Govender N, Lewis DA, et al. Part IV. Human infections and antibiotic resistance. South Afr Med J 2011;101:567-78.
6. Granizo JJ, Aguilar L, Casal J, et al. S. pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrobial Chemotherapy 2000;46:767-73.
7. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int J Antimicrobial Agents 2009;33:52-7.
8. Kariuki S, Dougan G. Antibacterial resistance in sub-Saharan Africa: an underestimated emergency. Ann NY Acad Sci 2014;1323:43-55.
9. Mudhune S, Wamae M, Network Surveillance for Pneumococcal Disease in the East African Region. Report on invasive disease and meningitis due to H. influenzae and S. pneumoniae from the Network for Surveillance of Pneumococcal Disease in the East African Region. Clin Infect Dis 2009;48:S147-52.
10. Ndiaye AG, Boye CS, Hounkponou E, et al. Antimicrobial susceptibility of select respiratory tract pathogens in Dakar, Senegal. J Infect Dev Ctries 2009;3:660-6.
11. Sahm DF, Brown NP, Thornsberry C, et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a global perspective. Postgrad Med 2008;120:16-23.
12. Samuel K, Gordon D. Antibacterial resistance in sub-Saharan Africa: an underestimated emergency. Ann NY Acad Sci 2014;1323:43-55.
13. Tamargo I, Fuentes K, Llop A, et al. High levels of multiple antibiotic resistance among 938 Haemophilus influenzae type b meningitis isolates from Cuba (1990-2002). J Antimicrobial Chemotherapy 2003;52:695-8.
14. Wang SR, Lo WT, Chou CY, et al. Low rate of nasopharyngeal carriage and high rate of ampicillin resistance for Haemophilus influenzae among healthy children younger than 5 years old in northern Taiwan. J Microbiol Immunol Infect 2008;41:32-40.
15. World Health Organization. World Health. Part III. Global health indicators. 2014. Available from: http://www.who.int/gho/publications/world_health_statistics/EN_WHS2014_Part3.pdf